EVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evotec SE is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive long-term potential and analysts have issued buy ratings with higher price targets, the recent financial performance shows declining net income and EPS, which could be a concern. Additionally, there are no strong trading signals or recent positive news to act as immediate catalysts. It is better to monitor the stock for now.
The MACD is positive and contracting, indicating a potential weakening of upward momentum. RSI is neutral at 67.531, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level of R1: 3.35, which could act as a barrier for further upward movement.
Analyst ratings from H.C. Wainwright and Berenberg with buy recommendations and higher price targets. The company has a leading position in drug discovery and is transitioning to a more capital-efficient structure.
Net income and EPS have significantly declined in the latest quarter. No recent news or significant trading trends from insiders or hedge funds. The stock has a low probability of significant short-term gains based on historical patterns.
In Q4 2025, revenue increased by 24.96% YoY, and gross margin improved by 48.66% YoY. However, net income dropped by -139.08% YoY, and EPS fell by -140.00% YoY, indicating profitability challenges.
H.C. Wainwright and Berenberg have issued buy ratings with price targets of $7 and EUR 10, respectively. Deutsche Bank has a hold rating with a lower price target of EUR 4.50.
